FDA has announced it has expanded the approved use of Humira (adalimumab), manufactured by Abbott Laboratories, to include treatment of moderate-to-severe ulcerative colitis in adults, according to a ...

Biologics in IBD: More Thoughtful Use Could Improve Outcomes The marketplace introduction of infliximab for the treatment of IBD did not reduce hospitalization or surgery rates in a large population ...

AbbVie has received good news from the European Medicines Agency for a new use of its anti-inflammation drug Skyrizi, one of the best-selling products in its portfolio, now that blockbuster drug ...

WASHINGTON, Aug 24 (Reuters) - Abbott Laboratories Inc may need to conduct additional trials of Humira to prove the blockbuster drug helps patients with ulcerative colitis, U.S. drug reviewers said on ...

AbbVie's stock has risen to an all-time high, raising the question of whether it's still a good buy, especially as the market multiples look elevated from a historical perspective. Progress on its ...

REDWOOD CITY, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS), today announced that YUSIMRY™ (adalimumab-aqvh) is now available for commercial sale in the United States at a ...

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie's Humira are plummeting as the once-top-selling drug fights ...